Gilead Sciences Inc
NASDAQ:GILD

Watchlist Manager
Gilead Sciences Inc Logo
Gilead Sciences Inc
NASDAQ:GILD
Watchlist
Price: 104.88 USD -0.76% Market Closed
Market Cap: 130.7B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one GILD stock under the Base Case scenario is hidden USD. Compared to the current market price of 104.88 USD, Gilead Sciences Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GILD Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

4.5
P/S
P/S
Price to Sales
4.5
vs History
3
vs Industry
63
Median 3Y
3.4
Median 5Y
3.2
Industry
6.5
Forward
4.5
More Details
272.3
P/E
P/E
Price to Earnings
272.3
vs History
12
vs Industry
0
Median 3Y
20
Median 5Y
17.2
Industry
22
Forward
12.9
More Details
12.1
P/OCF
P/OCF
Price to OCF
12.1
vs History
6
vs Industry
12
Median 3Y
10.6
Median 5Y
9.2
Industry
18.4
More Details
11.7
P/FCFE
P/FCFE
Price to FCFE
11.7
vs History
47
vs Industry
11
Median 3Y
12.5
Median 5Y
11.4
Industry
23.4
More Details
6.8
P/B
P/B
Price to Book Value
6.8
vs History
3
vs Industry
14
Median 3Y
4.3
Median 5Y
4
Industry
2.2
More Details
5.1
EV/S
EV/S
Enterprise Value to Sales
5.1
vs History
3
vs Industry
50
Median 3Y
3.9
Median 5Y
3.7
Industry
7.1
Forward
5
More Details
6.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.5
vs History
3
vs Industry
50
Median 3Y
5
Median 5Y
4.7
Industry
8.7
More Details
10.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
10.7
vs History
19
vs Industry
11
Median 3Y
8.6
Median 5Y
8.3
Industry
3.3
Forward
9.7
More Details
13.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
13.4
vs History
19
vs Industry
9
Median 3Y
10.4
Median 5Y
10.1
Industry
3.1
Forward
11
More Details
13.4
EV/OCF
EV/OCF
Enterprise Value to OCF
13.4
vs History
11
vs Industry
11
Median 3Y
12
Median 5Y
10.7
Industry
4
More Details
14.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
14.1
vs History
11
vs Industry
9
Median 3Y
13
Median 5Y
11.4
Industry
2.6
More Details
3
EV/IC
EV/IC
Enterprise Value to IC
3
vs History
3
vs Industry
39
Median 3Y
2
Median 5Y
1.9
Industry
4.3
More Details

Multiples Across Competitors

GILD Competitors Multiples
Gilead Sciences Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Gilead Sciences Inc
NASDAQ:GILD
130.7B USD 4.5 272.3 10.7 13.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 837 576.7 -165 577.8 -201 064.3 -198 769.9
US
Abbvie Inc
NYSE:ABBV
303.1B USD 5.4 71.5 14.4 21.7
US
Amgen Inc
NASDAQ:AMGN
151.7B USD 4.5 37.1 15.3 27
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.6B USD 11.3 -232.7 25.4 26.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 022.2 -516 -561.9 -546.9
AU
CSL Ltd
ASX:CSL
117.1B AUD 4.9 27.2 16.8 21
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.2B USD 4.2 13.6 8.2 9.1
US
Seagen Inc
F:SGT
39.3B EUR 19.5 -59.7 -64.3 -58
NL
argenx SE
XBRU:ARGX
31.7B EUR 16.5 43.3 319.7 -2 355.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
29.8B USD 13.3 -107.1 -234 -159
P/S Multiple
Revenue Growth P/S to Growth
US
Gilead Sciences Inc
NASDAQ:GILD
Average P/S: 3 167 243.9
4.5
3%
1.5
FR
Pharnext SCA
OTC:PNEXF
34 837 576.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.4
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.3
10%
1.1
US
E
Epizyme Inc
F:EPE
2 022.2
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
7%
0.6
US
S
Seagen Inc
F:SGT
19.5
30%
0.6
NL
argenx SE
XBRU:ARGX
16.5
37%
0.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
13.3
28%
0.5
P/E Multiple
Earnings Growth PEG
US
Gilead Sciences Inc
NASDAQ:GILD
Average P/E: 77.5
272.3
187%
1.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 577.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
71.5
87%
0.8
US
Amgen Inc
NASDAQ:AMGN
37.1
44%
0.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -232.7 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516 N/A N/A
AU
CSL Ltd
ASX:CSL
27.2
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
12%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.7 N/A N/A
NL
argenx SE
XBRU:ARGX
43.3
26%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -107.1 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Gilead Sciences Inc
NASDAQ:GILD
Average EV/EBITDA: 58.6
10.7
7%
1.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 064.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.4
14%
1
US
Amgen Inc
NASDAQ:AMGN
15.3
17%
0.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
18%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.9 N/A N/A
AU
CSL Ltd
ASX:CSL
16.8
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
8.2
14%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.3 N/A N/A
NL
argenx SE
XBRU:ARGX
319.7
166%
1.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -234 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Gilead Sciences Inc
NASDAQ:GILD
Average EV/EBIT: 19.8
13.4
11%
1.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 769.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
21.7
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
27
31%
0.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.6
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -546.9 N/A N/A
AU
CSL Ltd
ASX:CSL
21
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.1
17%
0.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -58 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 355.4 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -159 N/A N/A

See Also

Summary
GILD intrinsic value, competitors valuation, and company profile.
DCF Valuation
GILD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GILD stock valuation using valuation multiples.
Wall Street Estimates
GILD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GILD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 247,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.